Amendments to the Specification:

At the end of the application, please replace the current Sequence Listing with the attached paper and computer-readable Sequence Listing.

Please replace the paragraph on page 5, lines 20-22, with the following rewritten paragraph:

2) Second extracellular loop: located between transmembrane domains 4 & 5 and corresponding to residues: **ITTCHDV** (SEQ ID NO: 12) which are conserved in PAR 1-3, while in PAR-4 only the three amino acids **CHD** are conserved.

Please replace the paragraph on page 6, line 1, with the following rewritten paragraphs:

~~**Fig. 1 shows**~~ **Figs. 1A-C** show the DNA sequence of human ThR (SEQ ID NO: 5) ~~and amino acid sequence (SEQ ID NO: 6) of human ThR~~ [1].

Fig. 1D shows the amino acid sequence of human ThR (SEQ ID NO: 6).

Please replace the paragraphs on page 7, lines 25-26, with the following rewritten paragraphs:

~~**Fig. 10 shows**~~**Figs. 10A-B** show the DNA sequence of PAR-3 (SEQ ID NO: 9).

~~**Fig. 11a shows**~~ **Figs. 11A-E** show the DNA sequence of PAR-4 (SEQ ID NO: 10).

~~**Fig. 11b**~~**Fig. 11F** shows the amino acid sequence of PAR-4 (SEQ ID NO: 11).

Please replace the paragraph beginning on page 8, line 27, with the following rewritten paragraph:

Plasmids and transfections: The DNA and amino acid sequences of ThR are show in Fig. 1 [1]. ThR in the antisense orientation (Fig. 2), consisting of ~~612~~ 548 nucleotides (from ~~(-)75 to (+)537~~nucleotides 64 to 611 of Fig. 1) was prepared and inserted into the eukaryotic expression plasmid, pcDNA III (Invitrogene, Carlsbad, CA) at the HindIII and EcoRI sties (Fig. 3). Antisense ThR cDNA was used for transient transfection experiments. Subconfluent (25-40%) MDS-435 breast cancer cells were grown in 60 mm culture dishes

and a total of 5-20 μg of DNA and DOTAP - transfection reagent (10 μg DOTAP/μg DNA; 4.5 h incubation, Boehringer Mannheim, Mannheim, Germany) were used for transfection. Cells were assayed 48-72 h following transfection.

Please replace the paragraph beginning on page 10, line 23, with the following rewritten paragraph:

Antibodies: We have raised anti-ThR antibodies directed toward a synthetic peptide (thrombin- receptor activating peptide; TRAP) corresponding to residues Ser42-Lys51 (i.e. S-F-L-L-R-N-P-N-D-K (SEQ ID NO: 13)). KLH conjugated peptide was injected to rabbits, and the immune serum was affinity purified. ELISA was performed on plates coated with the TRAP-peptide showing efficient positive identification at 1:25,600 dilution. Maximal response was obtained at 1:3,200 dilution. Monoclonal anti ThR Abs (mouse IgG1 clone IIaR-A) were used for Western blot analysis (Biodesign, ME, USA).

Please replace the paragraph beginning on page 15, line 17, with the following rewritten paragraph:

Similar antisense molecules may be prepared from other members of the PAR family, such as PAR-2 (SEQ ID NO: 8) (Fig. 9), PAR-3 (SEQ ID NO: 9) (~~Fig. 10~~Figs. 10A-B) and PAR-4 (SEQ ID NO: 10) (~~Fig. 11a~~Figs. 11A-E).